« Return to News | CROs/Service Providers

Averion Revenues Double Following Hesperion Acquisition

Tuesday, November 18, 2008 12:22 PM

Averion, a contract research organization (CRO) specializing in oncology, reported its third quarter revenues more than doubled following its acquisition of Swiss CRO Hesperion.

Net service revenue for the three months ended September 30 was $15.9 million, compared with $7.8 million for the same period last year. The Southborough, Mass.-based company’s direct expenses for the third quarter of 2008 increased $5.7 million over third quarter 2007 to $9.9 million. The Hesperion acquisition, completed in October 2007, contributed $5.4 million to those third quarter expenses.

“We continued to realize positive trends in our net service revenue despite the difficulties facing many of our clients who are currently seeking additional sources of funds,” said Averion CEO Markus Weissbach, M.D., Ph.D., in a company statement. “We continue to manage our business very carefully and capitalize on the efficiencies of our expanded international operations through the integration of Hesperion and Averion.”

Averion expanded its European operations last month with the opening of a Czech Republic office, and the CRO continues to look for other expansion opportunities (both geographically and in the services it provides), according to Weissbach. Averion has U.S. offices in California, Maryland and New York; and international offices in France, the Netherlands, the United Kingdom, Poland, Russia, Israel, Germany, Austria, Ukraine and the Czech Republic.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.